Akums Drugs has secured a significant €35 million per year contract in Europe, set to commence from FY27. The company aims for a ₹300 crore expansion, which includes sourcing materials from Zambia and focusing on CDMO growth. However, challenges remain with the production of Active Pharmaceutical Ingredients (APIs).

Akums Drugs' subsidiary has been slapped with a significant tax demand of around INR 73.7 crore, with the company itself owing INR 60.1 crore. This is due to disallowance under Section 37(1). The company intends to appeal and expects minimal long-term impact on its operations.

Akums Drugs anticipates a 25% standard tax rate in the upcoming fiscal year as their profits are becoming positive, with plans to reduce it further to 29% long-term.

Akums Drugs announces a planned investment of 300 crore INR in FY27 for expanding its oral solid facilities. The company also intends to seek growth through strategic acquisitions in specialized market sectors.

Akums Drugs plans to substantially decrease losses in the API (Active Pharmaceutical Ingredient) segment this fiscal year. The company aims to achieve monthly EBITDA profits, even as they continue to face annual losses overall.

Akums Drugs has restarted full production at its Haridwar facilities as of May 18, 2026. Unfortunately, a four-day halt in operations resulted in a delay of approximately Rs 20 crore worth of supplies.

Akums Drugs plans to achieve double-digit growth in their domestic branded medications, following industry production rates (IPM). This growth is anticipated through new product launches, brand reinforcement, and increased efficiency of their sales team.

Akums Drugs anticipates consistent income from its Trade Generics segment, with both revenue and EBITDA remaining steady. This particular business is forecasted not to cause significant fluctuations in the overall group's sales or profits.

Akums Drugs, a pharmaceutical company, is set to initiate $25M worth of commercial supplies in Zambia by Q2 of its fiscal year 2027. This move comes as part of a two-year partnership and will add approximately $25M annually to their CDMO (Contract Development and Manufacturing Organization) revenues for the fiscal years 2027 and 2028.

Akums Drugs has fully restarted production at their Uttarakhand facilities as of May 18, 2026. A recent four-day shutdown led to a significant revenue loss of approximately INR 20 crores, but the company is optimistic about recovery in the upcoming weeks.

Akums Drugs demonstrates a 5.8% revenue increase, signifying continuous business growth. The pharma company aims to secure a significant $200 million contract in Europe's CDMO market by fiscal year 28, potentially expanding its global footprint.

Akums Drugs has restarted production at its Haridwar facilities following a four-day hiatus, aiming to recover from a 20 crore INR supply delay due to the stoppage.

Despite a recent price drop, Akums Drugs has been deemed "very attractive" due to changing market dynamics in the sector, indicating renewed investor interest.

Akums Drugs & Pharmaceuticals reported unchanged Q4 earnings, marking a stabilization from previous decreases. Despite a decline in net profit over nine months, operational margins have shown improvement. Analysts at Marketsmojo have upgraded their rating for the company to "Hold".

Labor disruption in Uttarakhand temporarily impacted Akums Drugs' operations in Haridwar, but as of May 16, they have restored 70% of their activities. Fortunately, no property damage was reported and production losses are covered by insurance. The company expects to return to normal operations shortly.

Akums Drugs has been affected by labor disputes in the SIDCUL area of Haridwar since mid-May, leading to operational disruptions. The company is actively collaborating with employees and local officials to restore normal operations.

Akums Drugs reported strong recovery in the second half of FY26, with increased volumes and cost cuts significantly improving their Q4 margins. The company also shared their growth strategies for the future.

Akums Drugs has significantly increased its Quarter 4 PBT to 1.23 billion rupees compared to the previous year, boosted by a substantial deferred tax credit of 949 million rupees.

Major companies such as HAL, JSW Steel, Voltas, United Spirits, and Akums Drugs & Pharmaceuticals will unveil their Q4 financial results on May 14. Investors are eagerly awaiting these announcements to assess the performance of these businesses.

Akums Drugs will be discussing their FY26 financial results at a board meeting on May 14, 2026. The meeting's significance lies in the potential dividend recommendation and the reopening of trading following the result announcement.

Akums Drugs has broken out of a descending channel, indicating potential growth, backed by a bullish MACD crossover. The SMA is on the rise, along with high breakout volume and a bullish weekly candlestick, suggesting optimistic market sentiment for the pharmaceutical company.

Akums Drugs' AA (stable) long-term rating and A1 short-term rating are maintained by ICRA, due to robust CDMO growth, minimal debt levels, and good liquidity. However, the company faces competition pressures and rising raw material costs as challenges.

Akums Drugs and Pharmaceuticals Ltd has received positive reviews from ICRA, maintaining strong credit ratings for working capital limits and initiating a new commercial paper program. The company's CDMO revenue increased by 7% YoY to Rs. 2,533 crore in the first nine months of FY26 due to growth in volume and a significant EUR 100M contract, enhancing liquidity.

Akums Pharma has successfully breached its resistance trendline, indicating a potential positive shift in its price movement. The stock's pattern of higher lows, followed by a week of consolidation, and a surge in trading volume suggests that investors are increasingly accumulating the shares.